Evidence map›Paper›PMID 26503470›Full record

ArticleOncotarget2015

IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.

Pei Yang, Wei Zhang, Yinyan Wang, Xiaoxia Peng, Baoshi Chen, Xiaoguang Qiu, Guilin Li, Shouwei Li, Chenxing Wu, Kun Yao and 6 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 4 pooled it
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 4 syntheses or guidelines pooled it, 160 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. IDH mutant high-grade gliomas.Frontiers in molecular neuroscience · 2025
    Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. A Synopsis of Biomarkers in Glioblastoma: Past and Present.Current issues in molecular biology · 2024
    Review

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 2 countries.

Pei YangBeijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Wei ZhangBeijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Yinyan WangBeijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Xiaoxia PengDepartment of Epidemiology and Biostatistics, School of Public Health and Family Medicine, Capital Medical University, Beijing, China.
Baoshi ChenDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xiaoguang QiuDepartment of Radiation Therapy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Guilin LiDepartment of Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Shouwei LiDepartment of Neurosurgery, Beijing Sanbo Brain Hospital, Capital Medical University, Beijing, China.
Chenxing WuDepartment of Neurosurgery, Beijing Sanbo Brain Hospital, Capital Medical University, Beijing, China.
Kun YaoDepartment of Pathology, Beijing Sanbo Brain Hospital, Capital Medical University, Beijing, China.
Wenbin LiDepartment of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Wei YanDepartment of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jie LiCenter for Theoretic and Applied Neuro-Oncology, Division of Neurosurgery, University of California, San Diego, CA, USA.
Yongping YouDepartment of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Clark C ChenCenter for Theoretic and Applied Neuro-Oncology, Division of Neurosurgery, University of California, San Diego, CA, USA.
Tao JiangBeijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Beijing Institute of Neurosurgery · CNCapital Medical University · CNBeijing Sanbo Brain Hospital · CNUniversity of California, San Diego · USBeijing Shijitan Hospital · CNBeijing Tian Tan Hospital · CNJiangsu Province Hospital · CNNanjing Medical University · CN

Funding

Targeting Mechanisms of Acquired Temozolomide Resistance in GlioblastomaR01NS097649 · NINDS · UNIVERSITY OF MINNESOTA · PI CHEN, CLARK CHIN-CHUNG · 2016 to 2021
$1.7M
NINDS NIH HHS R01 NS097649
6 · The paper itself

Abstract

backgroundThe relative contribution of isocitrate dehydrogenase mutations (mIDH) and O6-methylguanine-DNA methyltransferase promoter methylation (methMGMT) as biomarkers in glioblastoma remain poorly understood.

methodsWe investigated the association between methMGMT and mIDH with progression free survival and overall survival in a prospectively collected molecular registry of 274 glioblastoma patients.

resultsFor glioblastoma patients who underwent Temozolomide and Radiation Therapy, OS and PFS was most favorable for those with tumors harboring both mIDH and methMGMT (median OS: 35.8 mo, median PFS: 27.5 mo); patients afflicted glioblastomas with either mIDH or methMGMT exhibited intermediate OS and PFS (mOS: 36 and 17.1 mo; mPFS: 12.2 mo and 9.9 mo, respectively); poorest OS and PFS was observed in wild type IDH1 (wtIDH1) glioblastomas that were MGMT promoter unmethylated (mOS: 15 mo, mPFS: 9.7 mo). For patients with wtIDH glioblastomas, TMZ+RT was associated with improved OS and PFS relative to patients treated with RT (OS: 15.4 mo v 9.6 mo, p < 0.001; PFS: 9.9 mo v 6.5 mo, p < 0.001). While TMZ+RT and RT treated mIDH patients exhibited improved overall survival relative to those with wtIDH, there were no differences between the TMZ+RT or RT group. These results suggest that mIDH1 conferred resistance to TMZ. Supporting this hypothesis, exogenous expression of mIDH1 in independent astrocytoma/glioblastoma lines resulted in a 3-10 fold increase in TMZ resistance after long-term passage.

conclusionsOur study demonstrates IDH mutation and MGMT promoter methylation status independently associate with favorable outcome in TMZ+RT treated glioblastoma patients. However, these biomarkers differentially impact clinical TMZ response.

Indexed as

DNA MethylationAdolescentAdultAgedAged, 80 and overAntineoplastic Agents, AlkylatingBiomarkers, TumorBrain NeoplasmsChemoradiotherapyDacarbazineDNA Modification MethylasesDNA Repair EnzymesFemaleFollow-Up StudiesGlioblastomaHumansAntineoplastic Agents, AlkylatingBiomarkers, TumorDacarbazineDNA Modification MethylasesDNA Repair EnzymesIDH1 protein, humanIDH2 protein, humanIsocitrate DehydrogenaseMGMT protein, humanTemozolomideTumor Suppressor ProteinsglioblastomasIDHMGMTradiationtemozolomide

Identifiers

PMID26503470
PMCPMC4747376
OpenAlexW2252317757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.